Skip to main navigation

Sorrento Therapeutics

Search

Client Header Links

  • Who We Are
    • Overview
    • History
    • Leadership
    • Board of Directors
  • Research
    • Pipeline
    • Covid-19
    • Immuno-Oncology
    • Pain
    • Lymphatic Delivery System
    • Product Candidates
  • Manufacturing
  • Subsidiaries
  • Partnership
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • SEC FILINGS
    • Stock
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • Contact IR
  • Career
  • Contact

News Releases

News Releases

Jan 29, 2023
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Jan 29, 2023
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Jan 09, 2023
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

Tools

  • Print

    Print

  • Email Alerts

    Email Alerts

  • RSS Feeds

    RSS Feeds

  • Email Page

    Email Page

© 2023 Sorrento Therapeutics. All Rights Reserved.

Footer

    Terms of Use Privacy Policy DMCA Trademarks Linking Policy
logo

Client Header Links

  • Who We Are
    • Overview
    • History
    • Leadership
    • Board of Directors
  • Research
    • Pipeline
    • Covid-19
    • Immuno-Oncology
    • Pain
    • Lymphatic Delivery System
    • Product Candidates
  • Manufacturing
  • Subsidiaries
  • Partnership
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • SEC FILINGS
    • Stock
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • Contact IR
  • Career
  • Contact